OMS643762

DRUG2 trials

Sponsors

Omeros Corporation

Conditions

Huntington's DiseaseSchizophrenia

Phase 2

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

CompletedNCT01952132

Omeros CorporationSchizophrenia

Start: 2013-09-30End: 2014-04-30Updated: 2018-10-22

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

TerminatedNCT02074410

Omeros CorporationHuntington's Disease

Start: 2014-01-31End: 2014-10-15Updated: 2018-10-22